5-Aminovaleric acid hydrochloride |
| カタログ番号GC12713 |
5-アミノ吉草酸塩酸塩は、γ-アミノ酪酸 (GABA) のメチレン同族体として作用し、弱い GABA アゴニストとして機能すると考えられています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 660-88-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5-Aminovaleric acid has been identified as an important five-carbon platform chemical, which can be used for the synthesis of polymers and other chemicals of industrial interest as well.
In vitro: 5-Aminovaleric acid, a GABA analog, was reported to be able to inhibit GABA uptake, inactivate GABA aminotransferase, and could also both agonize and antagonize GABAb receptors. In addition, 5-aminovaleric acid has been found to be able to increase glutamine concentrations, thus possibly compensating for the decreased concentration of brain glutamine [1].
In vivo: Animal study found that 5-aminovaleric acid-treated rats showed a 3.5-fold reduction in the number of seizures than PBS-treated rats. In addition, both groups showed similar seizure frequency (~1 seizure/day). However, the fraction of the most severe type of seizures increased over time in the PBS treated group, but not in the 5-aminovaleric acid treated group. Moreover, 5-aminovaleric acid treated rats experienced a 2.3- and 2.6-fold lower fraction of stage 4 and 5 seizures than PBS-treated rats [1].
Clinical trial: Aminocaproic acid has been approved by FDA for the treatment of acute bleeding caused by elevated fibrinolytic activity. It has also been used for the prevention of recurrent hemorrhage in patients with traumatic hyphema [https://en.wikipedia.org/wiki/Aminocaproic_acid].
Reference:
[1] Dhaher R,Damisah EC,Wang H,Gruenbaum SE,Ong C,Zaveri HP,Gruenbaum BF,Eid T. 5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy. Neurobiol Dis.2014 Jul;67:18-23.
| Cas No. | 660-88-8 | SDF | |
| Chemical Name | 5-aminopentanoic acid | ||
| Canonical SMILES | O=C(O)CCCCN | ||
| Formula | C5H11NO2 | M.Wt | 117.15 |
| 溶解度 | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 8.5361 mL | 42.6803 mL | 85.3606 mL |
| 5 mM | 1.7072 mL | 8.5361 mL | 17.0721 mL |
| 10 mM | 0.8536 mL | 4.268 mL | 8.5361 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *